Intest Res Search

CLOSE


‘Intestinal Research’ (Intest Res) is the joint official publication of the Asian Organization for Crohn's and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn's Foundation (India) (CCF, india).
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance.As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines.

Review

February 6, 2024


Screening and surveillance for hereditary colorectal cancer
Hee Man Kim, Tae Il Kim
Intest Res. 2024;22(2):119-130.

Review

February 1, 2024


Pathogenesis and biomarkers of colorectal cancer by epigenetic alteration
Chang Kyo Oh, Young-Seok Cho
Intest Res. 2024;22(2):131-151.

Original Article

January 5, 2024


Assessing quality of magnetic resonance enterography and its impact on disease assessment of ileal Crohn’s disease
Anuj Bohra, Declan J Connoley, Danny Con, et al.
Intest Res. 2024;22(2):152-161.

Original Article

January 22, 2024


Sarcopenia is common in ulcerative colitis and correlates with disease activity
Pardhu B Neelam, Rimesh Pal, Pankaj Gupta, et al.
Intest Res. 2024;22(2):162-171.

Original Article

April 25, 2024


Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
Taku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.
Intest Res. 2024;22(2):172-185.

Original Article

April 25, 2024


A survey of current practices in post-polypectomy surveillance in Korea
Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, et al.
Intest Res. 2024;22(2):186-207.

Original Article

February 6, 2024


Unraveling molecular similarities between colorectal polyps and colorectal cancer: a systems biology approach
Mehran Radak, Hossein Fallahi
Intest Res. 2024;22(2):199-207.

Use of thiopurines in inflammatory bowel disease: an update
Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, et al.
Intest Res. 2022;20(1):11-30.

Review

Epub April 15, 2021

Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intest Res. 2022;20(2):159-164.

Review

Epub April 29, 2022

Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intest Res. 2022;20(4):418-430.

Review

Epub December 2, 2021

The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment
Sang Hoon Kim, Yun Jeong Lim
Intest Res. 2022;20(1):31-42.

Review

Epub May 21, 2021

Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
Danny Con, Bridgette Andrew, Steven Nicolaides, et al.
Intest Res. 2022;20(1):101-113.

Original Article

Epub March 12, 2021

Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, et al.
Intest Res. 2023;21(1):61-87.

Review

Epub May 31, 2022

Management of inflammatory bowel disease in the COVID-19 era
Kyeong Ok Kim, Byung Ik Jang
Intest Res. 2022;20(1):3-10.

Review

Epub February 3, 2021

Endoscopic diagnosis and treatment of early colorectal cancer
Seung Wook Hong, Jeong-Sik Byeon
Intest Res. 2022;20(3):281-290.

Review

Epub July 26, 2022

Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, et al.
Intest Res. 2023;21(1):43-60.

Review

Epub October 18, 2022

Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis
Anupam K. Singh, Anuraag Jena, Praveen Kumar-M, et al.
Intest Res. 2022;20(1):134-143.

Original Article

Epub January 18, 2021

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, et al.
Intest Res. 2022;20(3):350-360.

Original Article

Epub July 23, 2021

The dietary practices and beliefs of British South Asian people living with inflammatory bowel disease: a multicenter study from the United Kingdom
Benjamin Crooks, Ravi Misra, Naila Arebi, et al.
Intest Res. 2022;20(1):53-63.

Original Article

Epub January 6, 2021

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, et al.
Intest Res. 2022;20(1):72-77.

Original Article

Epub February 3, 2021

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
Fares Ayoub, Matthew Odenwald, Dejan Micic, et al.
Intest Res. 2022;20(2):240-250.

Original Article

Epub February 8, 2022

An integrative review of physical activity in adults with inflammatory bowel disease
Suja P Davis, Patricia B. Crane, Linda P. Bolin, et al.
Intest Res. 2022;20(1):43-52.

Review

Epub January 22, 2021

Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease
Shigeki Bamba, Osamu Inatomi, Atsushi Nishida, et al.
Intest Res. 2022;20(3):370-380.

Original Article

Epub May 14, 2021

Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, et al.
Intest Res. 2022;20(1):114-123.

Original Article

Epub August 4, 2021

Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, et al.
Intest Res. 2022;20(1):64-71.

Original Article

Epub February 3, 2021

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Intest Res. 2023;21(1):110-125.

Original Article

Epub March 11, 2022

Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
Seung Yong Shin, Young Kim, Won-Seok Kim, et al.
Intest Res. 2023;21(1):148-160.

Original Article

Epub June 14, 2022

An evaluation of dietary adequacy among patients with constipation-predominant irritable bowel syndrome in Malaysia
Nor Hamizah Shafiee, Nurul Huda Razalli, Norfilza M. Mokhtar, et al.
Intest Res. 2022;20(1):124-133.

Original Article

Epub January 22, 2021

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
Anthony Buisson, Lisa Cannon, Konstantin Umanskiy, et al.
Intest Res. 2022;20(3):303-312.

Original Article

Epub August 4, 2021

Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity
Takato Maeda, Hirotake Sakuraba, Hiroto Hiraga, et al.
Intest Res. 2022;20(1):90-100.

Original Article

Epub January 22, 2021

Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
Kensuke Sakurai, Shigeru Furukawa, Takehiko Katsurada, et al.
Intest Res. 2022;20(1):78-89.

Original Article

Epub January 22, 2021

Landscape of inflammatory bowel disease in Singapore
Daren Low, Nidhi Swarup, Toshiyuki Okada, et al.
Intest Res. 2022;20(3):291-296.

Review

Epub January 7, 2022

Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease
Meng-Tzu Weng, I-Lun Shih, Chien-Chih Tung, et al.
Intest Res. 2022;20(2):224-230.

Original Article

Epub February 8, 2022

One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
Yuichi Matsuno, Takehiro Torisu, Junji Umeno, et al.
Intest Res. 2022;20(2):260-268.

Original Article

Epub April 29, 2022

Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer
Chan Hyung Lee, Seong-Joon Koh, Zaher A Radi, et al.
Intest Res. 2023;21(3):295-305.

Review

Epub May 31, 2023

Artificial intelligence for endoscopy in inflammatory bowel disease
Kento Takenaka, Ami Kawamoto, Ryuichi Okamoto, et al.
Intest Res. 2022;20(2):165-170.

Review

Epub January 7, 2022

An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intest Res. 2023;21(2):189-195.

Review

Epub May 31, 2022

  • Journal Impact Factor 4.9
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD

ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2024 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next
Close layer
prev next